BioSpace News Archive

Abdul Rahman bin Mohammed Al Owais, UAE Minister of Health and Prevention, signed a partnership agreement with Leif Johansson, Chairman of leading global pharmaceutical company AstraZeneca, as part of its strategy to enhance the outcomes of national indicators in the field of respiratory diseases and cancer, to achieve the objectives of the National Agenda 2021.

Vectra Provides Important Information to Help Rheumatologists Identify Patients at Increased Risk of Joint Damage

Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.

At the 26th United European Gastroenterology Week (UEGW) congress in Vienna, Janssen presented three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates.

Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.

What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting.

Crescendo Biologics Ltd today announces it has appointed Dr Richard Williams as SVP CMC and Development, as well as a strategic CDMO partner for its lead programme, CB307, a PSMA-targeted bispecific T-cell enhancer.

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

PhaseBio Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million.

The Senate passed the bill on October 3 in a 98 to 1 vote. The House passed its version a week earlier in a vote of 393 to 8. The legislation includes provisions to promote research into new pain management drugs and expands access to substance abuse treatment for Medicaid patients.